Boehringer Ingelheim to Use Seqster Platform


Patients in all studies can consent to longitudinal data use to accelerate RWE

Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.

Read more about the partnership.

Listen to a podcast with Seqster CEO & Co-founder Ardy Arianpour.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.